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PSeverely Impaired von Willebrand
Factor-Dependent Platelet Aggregation
in Patients With a Continuous-Flow Left
Ventricular Assist Device (HeartMate II)
Jolanta Klovaite, MD,* Finn Gustafsson, MD, PHD,† Svend A. Mortensen, MD, DMSC,†
Kåre Sander, MD, DMSC,‡ Lars B. Nielsen, MD, PHD, DMSC*§
Copenhagen, Denmark
Objectives This study investigated the influence of the mechanical blood pump HeartMate II (HMII) (Thoratec Corporation,
Pleasanton, California) on blood coagulation and platelet function.
Background HMII is an implantable left ventricular assist device used for the treatment of heart failure. Patients treated with
HMII have increased bleeding tendencies.
Methods We measured agonist-induced platelet aggregation in 16 patients on HMII support.
Results The von Willebrand factor (vWF)-dependent ristocetin-induced platelet aggregation was impaired in 11 of the 16
patients, of which 12 had experienced at least 1 minor or major bleeding episode. The impaired ristocetin-induced
platelet aggregation was associated both with decreased specific activity of plasma vWF, presumably due to lack of
high molecular weight vWF multimers, as well as with attenuated function of the platelets themselves.
Conclusions The results imply that HMII treatment is associated with impaired platelet aggregation, which may contrib-
ute to an increased tendency to bleed. (J Am Coll Cardiol 2009;53:2162–7) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.048o
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(eft ventricular assist devices (LVADs) are mechanical
lood pumps used for the treatment of severe heart failure
e.g., as a bridge to heart transplantation, myocardial recov-
ry, or as long-term destination therapy). HeartMate II
HMII) (Thoratec Corporation, Pleasanton, California) is
mong the most commonly used LVAD systems (1,2).
Exposure of the blood to foreign surfaces may activate the
oagulation system. Hence, systemic anticoagulation with
itamin K and platelet inhibitors are recommended in
MII-treated patients (2). However, an increased tendency
o bleed above what is normally observed in patients
eceiving anticoagulation treatment has been observed at
oth early and late stages after HMII implantation (3).
The HMII contains an axial-flow pump that draws blood
rom the left ventricle and continuously pumps it into the
scending aorta, exposing the blood to high shear stress (4).
igh shear stress increases the susceptibility to proteolysis
rom the Departments of *Clinical Biochemistry, †Cardiology, and ‡Thoracic
urgery, Rigshospitalet, and the §Department of Biomedical Sciences, University of
openhagen, Copenhagen, Denmark.m
Manuscript received November 11, 2008; revised manuscript received February 6,
009, accepted February 10, 2009.f the largest von Willebrand factor (vWF) multimers (5,6),
ecreasing the ability of vWF to induce platelet aggregation.
ence, exposure of the blood to high shear stress might
mpose an acquired form of von Willebrand disease with
ualitative vWF defects and increased bleeding tendencies.
uch a pathogenic mechanism may explain the tendency to
leed of patients with aortic stenosis (7–9) or defects of
ardiac septae (10). vWF-dependent platelet aggregation
nvolves the binding of vWF to the GPIb-IX-V glyco-
rotein receptor complex on platelets. Exposure of the blood
o shear stress (e.g., during hemodialysis) also results in
efective GPIb-IX-V receptor function (11,12), which in-
reases bleeding tendency. The aim of this study was to
nvestigate the putative impact of HMII treatment on blood
oagulation and specifically to test the hypothesis that
MII may impair vWF-dependent platelet aggregation.
ethods
atients. We studied 12 men and 4 women, 19 to 63 years of
ge, in whom a HMII had been implanted 17 to 459 days
mean 151 days) previously. The indication for HMII treat-
ent was end-stage dilated (n  10) or ischemic (n  6)
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eight heparin and warfarin were initiated when post-
perative bleeding was acceptable, typically on day 2 after
urgery. In patients with underlying ischemic heart disease,
spirin was added, if tolerated. In case of manifest throm-
oembolic events, further platelet inhibition with clopi-
ogrel was initiated. The international normalized ratio
INR) was monitored closely, and if it decreased below 1.8,
ow molecular weight heparin was initiated until the INR
as 2. At the time of the present study, all patients
eceived warfarin, 5 received aspirin, and 1 of these patients
lso received clopidogrel. Five patients underwent heart
ransplantation (HTx) after 166 to 392 days (mean 295
ays) of treatment with HMII.
We also investigated hospitalized patients with conges-
ive heart failure (CHF) (ejection fraction20%; New York
eart Association functional class III to IV) due to dilated
n  4) or ischemic (n  5) cardiomyopathy and 6
utpatients who were receiving warfarin therapy because of
revious venous thrombosis (INR 2.4 to 4.1). Seven of
he patients with CHF received aspirin, with 1 of these
atients also receiving clopidogrel and 1 warfarin. Clin-
cal data were obtained from patient medical records.
ontrol samples were obtained from healthy staff members
t the Department of Clinical Biochemistry, Rigshospitalet,
openhagen.
iochemical analyses. Blood was anticoagulated with
.8% sodium citrate (Vacuette, Greiner Bio-One GmbH,
remsmünster, Austria). Platelet-rich plasma (PRP) was
repared by centrifugation at 200 g for 10 min at 21 to
3°C. The remaining blood was recentrifuged at 2,400 g for
5 min to obtain platelet-poor plasma (PPP). Plasma for
iochemical analysis was analyzed immediately, or stored at
80°C within 2 h after blood collection.
Laboratory analyses were conducted at the Department of
linical Biochemistry, Rigshospitalet. Plasma von Wille-
rand factor antigen (vWF:Ag) was measured with sand-
ich enzyme-linked immunosorbent assay by the use of
ntibodies from DAKO-Cytomation, SA (Trappes,
rance). The von Willebrand factor ristocetin-cofactor ac-
ivity (vWF:RCo) was measured with reagents and the BCT
nstrument from Dade Behring (Marburg, Germany). Mul-
imeric patterns of vWF were determined by sodium dode-
yl sulfate-agarose gel electrophoresis and western blotting
t the Department of Clinical Biochemistry, Malmö Uni-
ersity Hospital, Malmö, Sweden. Scanned images were
nalyzed with ImageJ (National Institutes of Health, Be-
hesda, Maryland). We measured a disintegrin and metal-
oproteinase with a thrombospondin type 1 motif, 13
ADAMTS-13) activity with reagents from Pepta Nova
Sandhausen, Germany). Glycocalicin was measured with
n enzyme-linked immunosorbent assay (Glycocalicin EIA
it, Takara Biomedical, Ohtsu, Japan).
latelet aggregation. PRP was mixed with autologous
PP to obtain a final platelet count of 250  109/l.
latelet aggregation after addition of agonists was mea- rured at 37°C in a Whole Blood
umi-Aggregometer 560 CA
Chrono-log Corporation, Hav-
rtown, Maryland) after the ad-
ition of adenosine diphosphate
ADP) (5 mol/l), collagen (2
g/ml), arachidonic acid (1
mol/l), or ristocetin (1.25 mg/
l) (Triolab, Copenhagen, Den-
ark). We measured the release
f adenosine triphosphate with
HRONO-LUME reagent (Trio-
ab). Aggregation was expressed as
ercent of the maximal aggrega-
ion obtained 8 min after the ad-
ition of agonists. Patient samples
ere always analyzed in parallel
ith platelets from a healthy con-
rol subject. When ristocetin-
nduced platelet aggregation was
mpaired, patient PRP was mixed
ith normal PPP (1  3), and
ormal PRP was mixed with pa-
ient PPP (1  3) before the ad-
ition of ristocetin (1.25 mg/ml).
inal platelet counts in mixtures
ere 109 31 109/l and 122
2  109/l when patient platelets and normal platelets were
sed, respectively.
tatistical analysis. The results are mean  SD unless
therwise indicated. Statistical analyses were conducted
ith Prism software (version 2.0, Graph Pad, San Diego,
alifornia). Two-group comparisons were made with the
tudent t test.
esults
f 16 HMII-treated patients, 12 had major or minor
leeding (Table 1). None had any history of increased
leeding tendency before HMII implantation. Two patients
ad suspected thromboembolic events (Table 1). Two other
atients exhibited temporary bilateral loss of vision and
ateralized motor deficits in the post-operative phase,
espectively. In both cases, cerebral computed scans were
ormal and did not reveal cerebral infarction (or bleed-
ng) (Table 1).
Changes in blood coagulation parameters could not
xplain the increased bleeding tendency (Table 2). How-
ver, ristocetin-induced platelet aggregation was severely
mpaired in patients with a bleeding history (Table 1,
ig. 1A). We found that ADP-induced platelet aggrega-
ion was moderately reduced in 7 patients, of whom 2
eceived aspirin (Fig. 1A). Collagen- and arachidonic
cid-induced platelet aggregation (and release of adeno-
ine triphosphate) was only abnormal in 1 patient who
Abbreviations
and Acronyms
ADAMTS-13  a disintegrin
and metalloproteinase with
a thrombospondin type 1
motif, 13
ADP  adenosine
diphosphate
CHF  congestive heart
failure
HMII  HeartMate II
HTx  heart
transplantation
INR  international
normalized ratio
LVAD  left ventricular
assist device
PPP  platelet-poor plasma
PRP  platelet-rich plasma
vWF  von Willebrand
factor
vWF:Ag  von Willebrand
factor antigen
vWF:RCo  von Willebrand
factor ristocetin-cofactor
activityeceived both aspirin and clopidogrel (Fig. 1A).
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Platelet Aggregation in HeartMate II Patients June 9, 2009:2162–7To differentiate between plasma and platelet defects in
atients with impaired ristocetin-induced platelet aggrega-
ion, we mixed platelets from the patients treated with
MII with normal plasma (or vice versa) before studying
latelet aggregation. Seven of the 11 patients displayed signs
f impaired ability of both plasma and platelet factors to
ediate ristocetin-induced platelet aggregation (Fig. 1B).
wo patients displayed normal ristocetin-induced plate-
et aggregation when their platelets were mixed with
ormal plasma, and 2 patients had normal platelet
ggregation when their plasma was mixed with normal
latelets (Fig. 1B).
aboratory Values, Anticoagulation, Bleeding, andhr mb tic/Neurological History i HMII-Treated Patients Before a
Table 1 Laboratory Values, Anticoagulation, Bleeding, andThrombotic/Neurological History in HMII-Treated Patie
ID #
Ristocetin-Induced Platelet
Aggregation (%)
ADP-Induced Platelet
Aggregation (%)
Specific Activity
of vWF*
Before HTx
1 3 98 0.5
2 3 46 0.4
3 4 22 0.4
4 4 ND 0.5
5 5 ND 0.3
6 5 46 0.5
7 5 48 0.8
8 8 40 0.4
9 17 ND 0.6
10 19 23 0.5
11 44 59 0.8
12 64 42 0.8
13 72 76 0.8
14 73 74 1.0
15 75 90 0.6
16 79 64 0.6
After HTx
3 62 50 1.0
4 72 77 1.0
5 87 71 1.0
7 91 77 0.9
9 72 59 0.9
vonWillebrand factor ristocetin-cofactor activity (vWF:RCo) divided by vonWillebrand factor antige
ccurred in relationship with operative procedures. Patient 3 received 11 portions, patient 5 rece
ransplantation (HTx). Patient 5 also had major bleeding after implantable cardioverter-defibrillat
reatment. Patient 6 received blood transfusions after epistaxis; patient 8 received blood transfus
A  aspirin; ADP  adenosine-induced platelet aggregation; C  clopidogrel; D  dipyridamole
asic Laboratory Values of HMII-Treated Patients Before and After
Table 2 Basic Laboratory Values of HMII-Treated Patients Befo
Laboratory Values Patients With CHF (n  9) Patients W
Hemoglobin (mmol/l) 8.3 1.3 7
Platelet count ( 109/l) 230 93.4 26
INR 1.2 0.3 2
APTT (s) 29 3 3
Fibrinogen (mol/l) 13.4 4.7 15
D-dimer (mg/l) 0.8 0.6 2
C-reactive protein (mg/l) 15 15 3
Factor VIII (kIU/l) 1.82 0.8 1.5alues are mean  SD. *Warfarin was stopped after HTx.
APTT  activated partial thromboplastin time; CHF  congestive heart failure; INR  international norack of high-molecular weight vWF multimers in
MII-treated patients. The average plasma concentrations
f vWF protein (vWF:Ag) and activity (vWF:RCo) were 1.6
0.7 kIU/l and 1.0 0.6 kIU/l, respectively. Hence, although
WF:Ag was elevated, as previously observed in patients with
HF (13), 11 of 16 patients treated with HMII had decreased
pecific activity of plasma vWF (vWF:RCo/vWF:Ag) (Fig.
A), and vWF specific-activity was lowest in patients with a
istory of severe bleeding (Fig. 2A). The patients treated with
MII had fewer large vWF multimers than healthy control
atients (Figs. 2B and 2C). This finding was not due to
ncreased plasma ADAMTS-13 levels, which were normal
ter HTx
efore and After HTx
k of High Molecular
ht vWF Multimers† Anticoagulation Bleeding History
Neurological and
Thrombotic History
Yes W Minor Watershed infarct
Yes W Minor TIA
Yes W, A Major‡ None
Yes W, A Minor None
Yes W, A Major‡ None
Yes W Major§ None
Yes W None None
Yes W Major§ None
Yes W, A Major‡ None
Yes W, A, C Minor None
Yes W None None
Yes W None Retinal artery embolus
Yes W None TIA
Yes W Minor None
Yes W Minor None
Yes W Minor None
No No None None
No No None None
No A, D None None
No No None None
No No None None
:Ag). †Assessed by the use of sodium dodecyl sulfate-agarose gel electrophoresis. ‡Major bleeding
7 portions, and patient 9 received 15 portions of packed red blood cells within 24 h after heart
tion. §These individuals had both major and minor bleeding episodes during HeartMate II (HMII)
r gastrointestinal bleeding.
not determined; TIA  transient ischemic attack; vWF  von Willebrand factor; W  warfarin.
and Patients With CHF
d After HTx and Patients With CHF
II (n  16) HMII Patients After HTx (n  5) Reference Interval
.4 7.6 0.6 7.0–10.0
3.7 299 69.5 150–400
.5 1.1 0.1* 1.3
25 3 23–35
12 1.4 5.3–10.3
.4 0.4 0.4 0.5
8 15 18 10
.6 2.15 0.7 0.5–1.49nd Af
nts B
Lac
Weig
n (vWF
ived 1
or inserHTx
re an
ith HM
.3 1
4 8
.3 0
8 7
.2 5
.2 2
5 4
3 0malized ratio; other abbreviations as in Table 1.
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Figure 2 Specific Activities and Multimeric
Patterns of Plasma vWF in HMII-Treated Patients
(A) Specific activities of plasma vWF in HMII-treated patients. Patients were
divided into those with a history of major, minor, or no bleeding. The dotted hori-
zontal line indicates the lower boundary of the reference interval of vWF:RCo/
vWF:Ag in healthy individuals. The specific activity of plasma vWF was calculated
as vWF:RCo divided by vWF:Ag. The p value is derived from a Student t test com-
paring patients with major bleeding with patients with no bleeding. (B) Western
blot of plasma vWF multimers in 3 representative HMII-treated patients before HTx
(2 healthy controls subjects with normal vWF multimeric pattern are shown for
comparison). The arrow indicates the direction of protein migration during gel elec-
trophoresis. (C) Distribution of vWF staining between high and low molecular
weight multimers (assessed by densitometry of vWF bands) in HMII-treated
patients (solid circles, n  16), HMII-treated patients after HTx (open circles, n 
5) and patients with CHF (solid squares, n  9), and healthy control patients
(open squares, n  8). Values are expressed as a percentage of total staining and
shown as mean  SEM. CHF  congestive heart failure; HTx  heart transplanta-
tion; vWF  von Willebrand factor; vWF:Ag  von Willebrand factor antigen; vWF:
RCo  von Willebrand factor ristocetin-cofactor activity; other abbreviations as in
Figure 1.A
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Figure 1 Agonist-Induced Platelet
Aggregation in HMII-Treated Patients
(A) Platelet aggregation after stimulation with adenosine diphosphate (ADP),
collagen, arachidonic acid, or ristocetin. Platelet-rich plasma (PRP) was incu-
bated for 8 min at 37°C with the indicated agonists. Results are expressed as
percentages of the maximal aggregation. Reference intervals are shown as
vertical bars (64% to 98%, 72% to 94%, 66% to 100%, and 64% to 100% for
ADP-, collagen-, arachidonic acid-, and ristocetin-induced platelet aggregation,
respectively). A sample from a healthy individual (laboratory staff) was always
analyzed in parallel with patient samples. Lines connect data from the same
patient. Black circles indicate patients receiving aspirin. (B) Ristocetin-induced
platelet aggregation in mixtures of plasma and platelets from patients (Pt.) and
healthy control patients (N). To discriminate between the effect of plasma and
platelet factors in patients with impaired ristocetin-induced platelet aggrega-
tion, patient platelets were mixed with plasma from a healthy person, or
patient plasma was mixed with platelets from a healthy person, before the
measurement of ristocetin-induced platelet aggregation (see the Methods sec-
tion for details). Lines connect data from the same patient. The dotted hori-
zontal line indicates the lower boundary of the reference interval in healthy
individuals. HMII  HeartMate II.
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Platelet Aggregation in HeartMate II Patients June 9, 2009:2162–71.2  0.4 AU/l; reference interval: 0.75 to 1.40 AU/l) in the
MII-treated patients.
ormalized vWF-dependent platelet aggregation after
Tx. Ristocetin-induced platelet aggregation (Fig. 3A),
lasma vWF-specific activity (Fig. 3B), and vWF multi-
eric distribution (Figs. 2C and 3C) were all normalized
fter HTx. Also, patients with CHF and patients receiv-
ng warfarin because of a previous venous thrombosis had
ormal ristocetin-induced platelet aggregation (Fig. 3A)
nd plasma vWF-specific activity (Fig. 3B). Patients with
HF also had normal vWF multimeric distribution
Fig. 2C).
iscussion
he present results imply that HMII treatment is associated
ith impaired platelet aggregation, which may contribute to
n increased tendency of bleeding in patients. The most
triking finding was that 11 of 16 HMII-treated patients
ad impaired ristocetin-induced platelet aggregation and
hat 9 of the 10 patients with severely impaired ristocetin-
nduced platelet aggregation had a history of minor or major
leedings. The impaired platelet aggregation was most
ikely due to the HMII treatment because each of the 5
atients examined had normalized platelet aggregation after
Tx. We examined whether the defect ristocetin-induced
latelet aggregation was due to plasma and/or platelet
actors. The results suggest that both platelet and plasma
actors and often a combination of the 2 contributed toward
he observed abnormality.
The specific activity of vWF was decreased in HMII-
reated patients. This finding was probably at least in part
ue to the lack of HMW vWF multimers. As such, HMII
ppears to induce a secondary VWD type 2 similar to what
as previously been observed in patients with aortic stenosis
7–9) and other cardiac defects (10). This finding is in
greement with those recently reported by Geisen et al.
14). Although the specific activity of plasma vWF was
ecreased in HMII-treated patients, the vWF activity was
till within the normal range. Therefore, the lack of HMW
ultimers may not fully account for the plasma factor
eading to impaired ristocetin-induced platelet aggregation.
ence, it is conceivable that the plasma from HMII-treated
atients might contain 1 or more factors that actually inhibit
he ristocetin-induced platelet aggregation. One such puta-
ive factor could be fragments of vWF generated during the
oss of HMW multimers (15,16).
The present findings emphasize a novel aspect of HMII
reatment. Thus, it seems important to uncover how im-
aired platelet function affects the risk of bleeding in
MII-treated patients. The results, albeit based on a rather
mall number of patients, suggest that the risk of bleeding in
MII-treated patients due to impaired platelet aggregation
ay be significant, and the authors of future studies should
lso address whether patients on LVADs with abnormal
latelet aggregation would be better off without routineHM II HTx CHF Warfarin
HM II
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Figure 3
Normalization of the Ristocetin-Induced
Platelet Aggregation and Plasma vWF-Specific
Activities and Multimeric Patterns After HTx
(A) Ristocetin-induced platelet aggregation and (B) specific activity of plasma vWF
(calculated as vWF:RCo divided by vWF:Ag) in 5 HMII-treated patients before and
after HTx. Nine patients with CHF and 6 outpatients in anticoagulant therapy with
warfarin (international normalized ratio 2.4 to 4.1) are shown for comparison. The
dotted horizontal lines indicate the lower boundaries of the reference intervals in
healthy individuals. Lines connect data from the same patient. (C) Western blot of
plasma vWF multimers after HTx in 2 representative HMII-treated patients; a HMII-
treated patient lacking high molecular weight multimers and a healthy control
patient with vWF normal multimeric pattern are shown for comparison. The arrow
indicates the direction of protein migration. Abbreviations as in Figure 2.
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nd/or ADP-induced platelet aggregation is impaired.
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